10-K Decoder · All companies

Vanda Pharmaceuticals Inc.

VNDA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$216M$199M+8.7%
Operating income−$151M−$40.7M−272%
Net income−$220M−$18.9M−1,067%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Oct 29, 2026

$Q3 2026Year earlierChange
Revenue$69.8M$56.3M+24.0%
Operating income−$23.5M−$31.3M+24.9%
Net income−$22.6M−$22.6M+0.0%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Vanda Pharmaceuticals's revenue in FY2025?
$216M in FY2025 (Fiscal year ended Dec 31, 2025), +8.7% vs $199M a year earlier, per its 10-K filed Feb 2026.
Was Vanda Pharmaceuticals profitable in FY2025?
No: net income was −$220M and operating income −$151M in FY2025.
What was Vanda Pharmaceuticals's revenue in Q3 2026?
$69.8M (+24.0% vs a year earlier), per its Form 10-Q filed Oct 29, 2026.